|
1.
|
|
7 p, 1.1 MB |
Multidisciplinary management of head and neck cancer : First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)
/
Maños, Manuel (Hospital Universitari de Bellvitge) ;
Giralt López de Sagredo, Jordi (Hospital Universitari Vall d'Hebron) ;
Rueda Domínguez, Antonio (Hospital Costa del Sol (Marbella)) ;
Cabrera, Joaquín (Hospital Infanta Cristina (Badajoz)) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Marruecos, Jordi (Institut Català d'Oncologia Girona) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Rodrigo, Juan Pablo (Hospital Universitario Central de Asturias) ;
Castelo Fernández, Beatriz (Hospital Universitario La Paz (Madrid)) ;
Martínez-Galán, Joaquina (Hospital Universitario Virgen de las Nieves (Granada)) ;
Arias-De-La-Vega, Fernando Carrillo (Complejo Hospitalario de Navarra) ;
Chaves, Manuel (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ;
Herranz, Jesús (Complejo Hospitalario Universitario de A Coruña) ;
Arrazubi, Virginia (Hospital de Basurto (Bilbao, Biscaia)) ;
Basté, Neus (Hospital Universitari Vall d'Hebron) ;
Castro, Almudena Vizcaya (Hospital Universitario La Paz (Madrid)) ;
Mesía, Ricard (Institut Català d'Oncologia (L'Hospitalet de Llobregat)) ;
Universitat Autònoma de Barcelona
Head and neck cancer is one of the most frequent malignances worldwide. Despite the site-specific multimodality therapy, up to half of the patients will develop recurrence. Treatment selection based on a multidisciplinary tumor board represents the cornerstone of head and neck cancer, as it is essential for achieving the best results, not only in terms of outcome, but also in terms of organ-function preservation and quality of life. [...]
2017 -  10.1016/j.oraloncology.2017.04.004
Oral Oncology, Vol. 70 (july 2017) , p. 58-64
|
|
|
2.
|
|
8 p, 509.4 KB |
GEIS-21 : A multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish sarcoma group (GEIS)
/
Mora, J. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Castañeda, A. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Perez-Jaume, S. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Maradiegue, E. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Valverde, C. (Hospital Universitari Vall d'Hebron) ;
Martin-Broto, J. (Universidad de Sevilla) ;
Garcia Del Muro, X. (Hospital Universitari de Bellvitge) ;
Cruz, O. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Cruz, J. (Hospital Universitario de Canarias (La Laguna)) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Maurel, J. (Hospital Clínic i Provincial de Barcelona) ;
Vaz, M.A. (Hospital Ramón y Cajal) ;
De Alava, E. (Universidad de Sevilla) ;
De Torres, C. (Hospital Sant Joan de Déu (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
First Spanish trial of Ewing sarcoma (ES) including adults and children with the aim to test the efficacy of Gemcitabine and Docetaxel (G/D) in newly diagnosed high-risk (HR) patients. This was a prospective, multicentric, non-randomised, open study for patients 1/240 years with newly diagnosed ES. [...]
2017 - 10.1038/bjc.2017.252
British Journal of Cancer, Vol. 117 Núm. 6 (may 2017) , p. 767-774
|
|
|
3.
|
|
19 p, 837.6 KB |
Malignant bone tumors (other than Ewing's) : clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)
/
Redondo, Andrés (Hospital Universitario La Paz (Madrid)) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Ortiz-Cruz, Eduardo (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Lopez-Martin, Jose A. (Hospital 12 de Octubre (Madrid)) ;
Correa, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Cruz, Josefina (Hospital Universitario de Canarias (La Laguna)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Santos, Aurelio (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
García del Muro, Xavier (Institut Catalá d'Oncologia Hospitalet) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. [...]
2017 - 10.1007/s00280-017-3436-0
Cancer Chemotherapy and Pharmacology, Vol. 80 Núm. 6 (january 2017) , p. 1113-1131
|
|
|
4.
|
|
8 p, 535.7 KB |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
/
Joensuu, Heikki (Helsinki University Hospital) ;
Blay, Jean-Yves (University Claude Bernard Lyon I) ;
Comandone, Alessandro (Gradenigo Hospital) ;
Martin-Broto, Javier (Hosp o Virgen del Rocío (Sevilla, Andalusia)) ;
Fumagalli, Elena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Del Muro, Xavier Garcia (Hospital Universitari de Bellvitge) ;
Adenis, Antoine (Centre Oscar Lambret) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Bouche, Olivier (University Hospital Robert Debre) ;
Italiano, Antoine (Comprehensive Cancer Centre. 2Institut Bergonie) ;
Bauer, Sebastian (University of Duisburg- Essen) ;
Barone, Carlo (University Hospital A. Gemelli) ;
Weiss, Claudia (Novartis Pharma GmbH) ;
Crippa, Stefania (Novartis Farma) ;
Camozzi, Maura (Novartis Farma) ;
Castellana, Ramon (Novartis Farmaceutica SA) ;
Le Cesne, Axel (Gustave Roussy) ;
Universitat Autònoma de Barcelona
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. [...]
2017 - 10.1038/bjc.2017.290
British Journal of Cancer, Vol. 117 Núm. 9 (2017) , p. 1278-1285
|
|
|
5.
|
|
5 p, 347.5 KB |
SEOM clinical guideline in nasopharynx cancer (2017)
/
Pastor, M. (Hospital Universitari i Politècnic La Fe (València)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
del Barco, E. (Complejo Asistencial Universitario de Salamanca) ;
Perez Segura, P. (Hospital Clínico San Carlos (Madrid)) ;
Astorga, B.G. (Hospital Universitario San Cecilio (Granada)) ;
Castelo, B. (Hospital Universitario La Paz (Madrid)) ;
Bonfill Abella, Teresa (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Martinez Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Grau, Juan Jose (Hospital Clínic i Provincial de Barcelona) ;
Mesía, Ricard (Institut Català d'Oncologia) ;
Universitat Autònoma de Barcelona
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiation therapy is an essential component of curative-intent of non-disseminated disease and the association of chemotherapy improves the rates of survival. [...]
2018 - 10.1007/s12094-017-1777-0
Clinical & Translational Oncology, Vol. 20 Núm. 1 (january 2018) , p. 84-88
|
|
|
6.
|
|
17 p, 345.4 KB |
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
/
Casali, P.G. (University of Milan) ;
Bielack, Stefan S (Klinikum Stuttgart-Olgahospital) ;
Abecassis, N. (Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE) ;
Aro, H.T. (Turku University Hospital (Turun Yliopistollinen Keskussairaala)) ;
Bauer, S. (University Hospital Essen (Alemanya)) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bonvalot, S. (Institut Curie) ;
Boukovinas, I. (Bioclinic Thessaloniki) ;
Bovee, J.V.M.G. (Leiden University Medical Center) ;
Brennan, B. (Royal Manchester Children's Hospital) ;
Brodowicz, Thomas (Medizinische Universität Wien) ;
Broto, J.M. (Hospital Universitario Virgen Del Rocio-CIBERONC) ;
Brugières, L. (Gustave Roussy Cancer Campus) ;
Buonadonna, A. (Centro di Riferimento Oncologico di Aviano) ;
De Alava, E (Universidad de Sevilla) ;
Dei Tos, A.P. (Ospedale Regionale di Treviso S.Maria di Cà Foncello) ;
Del Muro, X.G. (Integrated Unit ICO Hospitalet) ;
Dileo, P. (University College London Hospitals NHS Trust) ;
Dhooge, C. (Universitair Ziekenhuis Gent) ;
Eriksson, M. (Skåne University Hospital (Suècia)) ;
Fagioli, F. (University of Turin) ;
Fedenko, A. (N. N. Blokhin Russian Cancer Research Center) ;
Ferraresi, V. (Regina Elena National Cancer Institute) ;
Ferrari, A. (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Ferrari, S. (Istituto Ortopedico Rizzoli) ;
Frezza, A.M. (Istituto Nazionale Dei Tumori) ;
Gaspar, N. (Gustave Roussy Cancer Campus) ;
Gasperoni, S. (Azienda Ospedaliera Universitaria Careggi Firenze) ;
Gelderblom, H. (Leiden University Medical Centre) ;
Gil, T. (Institut Jules Bordet) ;
Grignani, G. (Candiolo Cancer Institute) ;
Gronchi, A. (University of Milan) ;
Haas, R.L. (Leiden University Medical Centre) ;
Hassan, B. (Oxford University Hospitals NHS Foundation Trust) ;
Hecker-Nolting, S. (Klinikum Stuttgart-Olgahospital) ;
Hohenberger, P. (Mannheim University Medical Center) ;
Issels, R. (University Munich) ;
Joensuu, H. (Helsinki University Central Hospital (HUCH)) ;
Jones, R.L. (Royal Marsden Hospital (Regne Unit)) ;
Judson, I. (Institute of Cancer Research) ;
Jutte, P. (University Medical Center Groningen) ;
Kaal, S. (Radboud University Medical Center) ;
Kager, L. (St. Medical University Vienna) ;
Kasper, B. (Mannheim University Medical Center) ;
Kopeckova, K. (University Hospital Motol) ;
Krákorová, D.A. (Masaryk Memorial Cancer Institute) ;
Ladenstein, R. (Medical University Vienna) ;
Le Cesne, A. (Gustave Roussy Cancer Campus) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lugowska, I. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Merimsky, O. (Tel Aviv Sourasky Medical Center (Ichilov)) ;
Montemurro, M. (Medical Oncology University Hospital of Lausanne) ;
Morland, B. (Birmingham Women's and Children's NHS Foundation Trust) ;
Pantaleo, M.A. (Policlinico S Orsola-Malpighi Università di Bologna) ;
Piana, R. (University of Turin) ;
Picci, P. (Istituto Ortopedico Rizzoli) ;
Piperno-Neumann, S. (Institut Curie) ;
Reichardt, P. (Helios Klinikum Berlin Buch) ;
Robinson, M.H. (Weston Park Hospital NHS Trust) ;
Rutkowski, P. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Safwat, A.A. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Schöffski, P. (University Hospitals Leuven (Bèlgica)) ;
Sleijfer, S. (Erasmus MC Cancer Institute) ;
Stacchiotti, S. (Istituto Nazionale Dei Tumori) ;
Strauss, S.J. (University College London Hospitals NHS Trust) ;
Sundby Hall, K. (Norwegian Radium Hospital) ;
Unk, M. (Institute of Oncology of Ljubljana) ;
Van Coevorden, F. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Van Der Graaf, W.T.A. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Whelan, J. (Sarcoma Unit. University College London Hospitals NHS Trust) ;
Wardelmann, E. (Universitätsklinikum Münster) ;
Zaikova, O. (Oslo University Hospital (Oslo, Noruega)) ;
Blay, Jean-Yves (Centre Leon Bernard and UCBL1) ;
Universitat Autònoma de Barcelona
2018 - 10.1093/annonc/mdy310
Annals of oncology, Vol. 29 (january 2018) , p. iv79-iv95
|
|
|
7.
|
|
12 p, 1.3 MB |
Cediranib in patients with alveolar soft-part sarcoma (CASPS) : a double-blind, placebo-controlled, randomised, phase 2 trial
/
Judson, Ian (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust) ;
Morden, James P. (The Institute of Cancer Research) ;
Kilburn, Lucy (The Institute of Cancer Research) ;
Leahy, Michael (The Christie NHS Foundation Trust) ;
Benson, Charlotte (The Royal Marsden NHS Foundation Trust) ;
Bhadri, Vivek (Chris O'Brien Lifehouse) ;
Campbell-Hewson, Quentin (Newcastle upon Tyne Hospitals NHS Foundation Trust) ;
Cubedo, Ricardo (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Dangoor, Adam (University Hospitals Bristol NHS Foundation Trust) ;
Fox, Lisa (The Institute of Cancer Research) ;
Hennig, Ivo (Nottingham University Hospitals NHS Trust (Regne Unit)) ;
Jarman, Katy (The Institute of Cancer Research) ;
Joubert, Warren (Princess Alexandra Hospital) ;
Kernaghan, Sarah (The Institute of Cancer Research) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
McNeil, Catriona (Chris O'Brien Lifehouse) ;
Seddon, Beatrice (University College London Hospitals NHS Foundation Trust) ;
Snowdon, Claire (The Institute of Cancer Research) ;
Tattersall, Martin (Chris O'Brien Lifehouse) ;
Toms, Christy (The Institute of Cancer Research) ;
Martinez Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Bliss, Judith M. (The Institute of Cancer Research) ;
Universitat Autònoma de Barcelona
Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. [...]
2019 - 10.1016/S1470-2045(19)30215-3
The Lancet. Oncology, Vol. 20 Núm. 7 (july 2019) , p. 1023-1034
|
|
|
8.
|
|
9 p, 1.5 MB |
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS) : Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
/
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Hindi, Nadia (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Cruz, Josefina (University Hospital Canarias) ;
Blay, Jean-Yves (Center Leon Berard (Lyon)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Italiano, Antoine (Institute Bergonie - Bourdeaux) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Gutierrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Rincón, Inmaculada (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Pérez Aguiar, José Luis (Hospital Universitario Canarias) ;
Romero, Jesús (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Morosi, Carlo (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Sunyach, Marie Pierre (Center Leon Berard) ;
Sanfilippo, Roberta (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
Romagosa, Cleofe (Hospital Universitari Vall d'Hebron) ;
Ranchere-Vince, Dominique (Center Leon Berard) ;
Dei Tos, Angelo (University of Padova) ;
Casali, Paolo G. (University of Milan) ;
Martin-Broto, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
Myxoid liposarcoma (ML) exhibits a special sensitivity to trabectedin (T) and radiation therapy (RT). Preclinical data suggest a synergistic effect. We aimed to study safety, feasibility and activity of the administration of pre-operative concurrent T and RT in patients affected by localized resectable ML. [...]
2019 - 10.1016/j.eclinm.2019.03.007
EClinicalMedicine, Vol. 9 (march 2019) , p. 35-43
|
|
|
9.
|
|
15 p, 2.6 MB |
Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas
/
Ballesteros Silva, Mónica Patricia (C/Sant Antoni Maria Claret) ;
Montero, N. (Universidad Tecnológica Equinoccial) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Urrútia, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Solà, Ivan (Institut d'Investigació Biomèdica Sant Pau) ;
Rada, Gabriel (Pontificia Universidad Católica de Chile) ;
Pardo-Hernandez, Hector (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Bonfill, X. (Xavier) (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Soft tissue sarcomas are a heterogeneous group of rare tumours of mesenchymal origin. Evidence mapping is one of the most didactic and friendly approaches to organise and summarise the range of research activity in broad topic fields. [...]
2019 - 10.1007/s12094-019-02069-z
Clinical & Translational Oncology, Vol. 21 Núm. 10 (january 2019) , p. 1398-1412
|
|
|
10.
|
|
12 p, 1.3 MB |
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
/
Serrano, Cesar (Vall d'Hebron Institut d'Oncologia) ;
Vivancos, Ana (Vall d'Hebron Institut d'Oncologia) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Matito, Judit (Vall d'Hebron Institut d'Oncologia) ;
Mancuso, Francesco M. (Vall d'Hebron Institut d'Oncologia) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Quiroga, Sergi (Hospital Universitari Vall d'Hebron) ;
Landolfi, Stefania (Hospital Universitari Vall d'Hebron) ;
Castro, Sandra (Hospital Universitari Vall d'Hebron) ;
Dopazo, Cristina (Hospital Universitari Vall d'Hebron) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili Manrique, Anna Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Menso, Maria M. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Martín-Broto, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sansó, Miriam (Vall d'Hebron Institut d'Oncologia) ;
García-Valverde, Alfonso (Vall d'Hebron Institut d'Oncologia) ;
Rosell Aluja, Jordi 1955- (Vall d'Hebron Institut d'Oncologia) ;
Fletcher, J.A. (Harvard Medical School) ;
George, S. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Carles, Joan (Hospital Universitari Vall d'Hebron) ;
Arribas, Joaquín V (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. [...]
2020 - 10.1186/s12885-020-6597-x
BMC Cancer, Vol. 20 Núm. 1 (may 2020) , p. 99
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
